Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance

Molecular Pharmacology

Volumn 52, Issue 5, 1997, Pages 798-806

  Li, Lan ^a,b   Keating, Michael J ^a   Plunkett, William ^a   Yang, L I Ying ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOUBLE STRANDED DNA; FLUDARABINE; FLUDARABINE TRIPHOSPHATE; NUCLEOTIDE DERIVATIVE; SINGLE STRANDED DNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CROSS LINKING; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0030775770     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.5.798     Document Type: Article

References (40)

1. Keating, M. J., P. McLaughlin, W. Plunkett, L. E. Robertson, S. O'Brien, V. Gandhi, V. Gregoire, L.-Y. Yang, and F. Cabanillas. Fludarabine: present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann. Oncol. 5:S79-S83 (1994).
2. Gandhi, V., and W. Plunkett. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem. Pharmacol. 38:3551-3558 (1989).
3. Catapano, C., F. W. Perrino, and D. J. Fernandes. Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate: a mechanism of DNA synthesis inhibition. J. Biol. Chem. 268:7179-7185 (1993).
4. Yang, L.-Y., L. Li, M. J. Keating, and W. Plunkett. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol. Pharmacol. 47:1072-1079 (1995).
5. Huang, P., and W. Plunkett. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analog is a critical event. Cancer Chemother. Pharmacol. 36:181-188 (1995).
6. Jones, J. C., W. Zhen, E. Reed, R. J. Parker, A. Sancar, and V. A. Bohr. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand crosslinks in Chinese hamster ovary cells. J. Biol. Chem. 266:7101-7107 (1991).
7. Sibghat-Ullah, I. Husain, W. Carlton, and A. Sancar. Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract. Nucleic Acids Res. 17:4471-4484 (1989).
8. Cole, R. S., Repair of DNA containing interstrand crosslinks in Escherichia coli: sequential excision and recombination. Proc. Natl. Acad. Sci. USA 70:1064-1068 (1973).
9. Van Houten, B., H. Gamper, S. R. Holbrook, J. E. Hearst, and A. Sancar. Action mechanism of ABC excision nuclease on a DNA substrate containing a psoralen crosslink at a defined position. Proc. Natl. Acad. Sci. USA 83:8077-8011 (1986).
10. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2:270-280 (1990).
11. Willie, A. H., J. F. R. Kerr, and A. R. Currie. Cell death: the significance of apoptosis, in International Review of Cytology (G. H. Bourne and J. F. Danielli, eds.). Academic Press, New York, 251-305 (1980).
12. Giles, F. J., S. O'Brien, H. M. Kantarjian, W. Plunkett, E. Estey, M. Beran, L.-Y. Yang, J. Seymour, L. E. Robertson, S. Lerner, and M. J. Keating. Sequential cis-platinum fludarabine, and arabinosyl cytosine (PFA) in patients with prior fludarabine therapy for chronic lymphocytic leukemia (CLL): a phase II study. Blood 88: Suppl. 1, 219b (1996).
13. Calabretta, B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res. 51: 4505-4510 (1991).
14. 2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148-1158 (1995).
15. McGahon, A., R. Bissonnette, M. Schmitt, K. M. Cotter, D. R. Green, and T. G. Cotter. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179-1187 (1994).
16. Nunez, G., and M. F. Clarke. The BCL-2 family of proteins: regulators of cell death and survival. Trends Cell Biol. 4:399-403 (1994).
17. s induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 7:1617-1623 (1996).
18. Cleaver, J. E., and K. H. Kreamer. Xeroderma pigmentosum, in The Metabolic Basis of Inherited Diseases (C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, eds). McGraw-Hill, New York, 2949-2971 (1989).
19. Zelle, B., and P. H. M. Lohman. Repair of UV-endonuclease-susceptible sites in the seven complementation groups of xeroderma pigmentosum A through G. Mutat. Res. 62:363-368 (1979).
20. Zhen, W., M. K. Evans, C. Haggerty, and V. A. Bohr. Deficient gene specific repair of cisplatin-induced lesions in xeroderma pigmentosum and Fanconi's anemia cell lines. Carcinogensis 14:919-924 (1993).
21. Kantor, G. J., L. S. Barsalou, and P. C. Hanawalt. Selective repair of specific chromatin domains in UV-irradiated cells from xeroderma pigmentosum complementation group C. Mutat. Res. 235:171-180, 1990.
22. Venema, J., A. van Hoffen, V. Karcagi, A. T. Natarajan, A. A. van Zeeland, and L. H. F. Mullenders. Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol. Cell Biol. 11:4128-4134 (1991).
23. Li, L, X.-M. Liu, A. B. Glassman, M. J. Keating, M. Stros, W. Plunkett, and L.-Y. Yang. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 57:1487-1494 (1997).
24. Yang, L.-Y., J. M. Trujillo, M. J. Siciliano, Y. Kido, Z. Siddick, and Y.-Z. Su. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum(II). Int. J. Cancer 53:478-485 (1993).
25. Chou, T.-C., and P. Talalay. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55 (1984).
26. 2+ concentration. Arch. Biochem. Biophys. 269:365-370 (1989).
27. Yang, L.-Y., Y. Z. Liu, H. H. Kantarjian, and M. J. Keating. DNA cross-linking and repair in cisplatin-resistant human cells following exposure to a new cisplatin analogue, CI-973. Int. J. Oncol. 5:597-602 (1994).
28. Vos, J. M. H., and P. Hanawalt. Processing of psoralen adducts in an active gene: repair and replication of DNA containing monoadducts and interstrand cross-links. Cell 50:789-799 (1987).
29. Fichtinger-Schepman, A. M. J., J. L. Van Der Veer, J. H. J. Den Hartong, P. H. M. Lohman, and J. Reedijk. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24:707-713 (1985).
30. Hansson, J., and R. D. Wood. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum (II). Nucleic Acids Res. 20:8073-8091 (1989).
31. Manley, J. L., A. Fire, M. J. Samuels, and P. A. Sharp. In vitro transcription: whole cell extract. Methods Enzymol. 101:568-582 (1983).
32. Shivji, M. K. K., M. K. Kenny, and R. D. Wood. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374 (1992).
33. Robine, P., C. J. Jones, M. Biggerstaff, T. Lindahl, and R. D. Wood. Complementation of DNA repair in xeroderma pigmentosum group A cell extracts by a protein with affinity for damaged DNA. EMBO J. 10:3913-3921 (1991).
34. Zdziencka, M. Z., L. Roza, A. Westerveld, D. Boostsma, and J. W. I. M. Simons. Biological and biochemical consequences of the human ERCC-1 repair gene after transfection into a repair-deficient CHO cell line. Mutat. Res. 183:69-74 (1987).
35. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA 93:6443-6447 (1996).
36. Pil, P. M., and S. J. Lippard. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science (Washington D. C.) 256:234-237 (1992).
37. Bruhn, S. L., P. M. Pil, J. M. Essigmann, D. E. Housman, and S. J. Lippard. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc. Natl. Acad. Sci. USA 89:2307-2311 (1992).
38. Huang, J.-C., D. B. Zamble, J. T. Reardon, S. J. Lippard, and A. Sancar. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA 91:10394-10398 (1994).
39. Brockman, R. W., F. M. Schabel, Jr., and J. A. Montgomery. Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-arabinofuranosyl-adenine. Biochem. Pharmacol. 26:2193-2196 (1977).
40. Gandhi, V., A. Kemena, M. J. Keating, and W. Plunkett. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk. Lymphoma 10:49-56 (1993).